Cancer Family
Respiratory System Neoplasm
CI-CAN-00000049Explore in graph →
Non-malignant2,725 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000049Explore in graph →
Clinical trials
11,608 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06334757 | Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure | unknown | Phase 2 | 46 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 28, 2024 | clinicaltrials |
| NCT05775068 | ARtificial Intelligence for Gross Tumour vOlume Segmentation(ARGOS) | unknown | — | 2,000 | Maastricht Radiation OncologyOTHER | 1 | Mar 27, 2024 |
| clinicaltrials |
| NCT06323265 | A Real-world Study of Adebrelimab Combined With Chemotherapy±Chest Radiotherapy in Patients With Extensive Stage Small Cell Lung Cancer | unknown | — | 50 | Hebei Medical University Fourth HospitalOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT06332287 | A Study of Trilaciclib Combined With Chemotherapy in the Treatment of Advanced NSCLC With Leptomeningeal Metastasis | unknown | Phase 2 | 25 | Jiangsu Province Nanjing Brain HospitalOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT06106152 | WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody | unknown | Early Phase 1 | 20 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT06331650 | A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer | unknown | Phase 2 | 30 | Guangzhou Institute of Respiratory DiseaseOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT02619448 | Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC | unknown | Early Phase 1 | 12 | State University of New York - Upstate Medical UniversityOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT06328049 | A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC | unknown | Phase 2 | 30 | Taixing People's HospitalOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT03322072 | Calypso Guided High Precision Stereotactic Ablative Radiosurgery for Lung TUmours Using Real-Time Tumour Tracking & Respiratory Gating(GPS) | unknown | N/A | 28 | CancerCare ManitobaOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT06321640 | Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies.(POSITive) | unknown | — | 265 | European Institute of OncologyOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT05669586 | Organoids Predict Therapeutic Response in Patients With Multi-line Drug-resistant Lung Cancer | unknown | Phase 2 | 50 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT05649046 | Structuring of a Lung Cancer Screening Program Including Clinical, Radiological and Biological Phenotyping Useful for the Development of Individualized Risk Prediction Tools: PREVALUNG ETOILE(PREVALUNG*) | unknown | N/A | 160 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT06314542 | Quantitative Evaluation of the Impact of Relaxing Eligibility Criteria for Lung Cancer Based on Real-world Data | unknown | — | 50,000 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT04903873 | A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 110 | EutilexINDUSTRY | 2 | Mar 15, 2024 | clinicaltrials |
| NCT06285058 | Deep Learning Model Predicts Pathological Complete Response of Lung Cancer Following Neoadjuvant Immunochemotherapy | unknown | — | 1,000 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Mar 13, 2024 | clinicaltrials |
| NCT05004974 | Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer | unknown | Phase 2 | 20 | The Fourth Affiliated Hospital of Zhejiang University School of MedicineOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05872867 | Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90) | unknown | Phase 1 | 54 | Wellmarker BioINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06277674 | Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI | unknown | Phase 2 | 20 | Guangzhou University of Traditional Chinese MedicineOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT06102369 | The Role of Narrow Band Imaging (NBI) Bronchoscopy in Detecting Bronchial Squamous Dysplasia in Lung Cancer | unknown | — | 110 | Indonesia UniversityOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT06293833 | Implementation of Lung Cancer Screening in the First Line Zone of ZORA (Flanders), Using a Low Dose CT-scan(ZORALCS) | unknown | N/A | 700 | University Hospital, AntwerpOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT04780217 | Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 42 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06287320 | The Predictive Biomarkers in Patients With Locally Advanced Non-small Cell Lung Cancer | unknown | — | 200 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 1, 2024 | clinicaltrials |
| NCT03865511 | MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib(MELROSE) | unknown | Phase 2 | 150 | Nantes University HospitalOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06281860 | Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration(PITHAC) | unknown | Phase 1 | 39 | Dr Jean Yannis PERENTESOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06282068 | AI Determine Malignancy of GGO on Chest CT | unknown | — | 100 | Chung Shan Medical UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06270992 | Oral Microbiome Diagnostics of Lung Cancer | unknown | — | 676 | TC Erciyes UniversityOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT06267144 | Detection of Minimal Residual Disease in Resectable Stage II-IIIB Non-small Cell Lung Cancer | unknown | — | 20 | The First Hospital of Jilin UniversityOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06267170 | A Multicenter, Real-world Study of Adebrelimab in the Treatment of Extensive Stage Small Cell Lung Cancer(SCLC) | unknown | — | 288 | Henan Cancer HospitalOTHER_GOV | 0 | Feb 20, 2024 | clinicaltrials |
| NCT03924466 | Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients(VUBAR) | unknown | Phase 2 | 55 | Universitair Ziekenhuis BrusselOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT06262555 | Novel Light Delivery Method for Performing Transbronchial Photodynamic Therapy for Peripheral Lung Cancer | unknown | N/A | 3 | Taoyuan General HospitalOTHER_GOV | 1 | Feb 16, 2024 | clinicaltrials |
| NCT06258954 | Effect of 3D-printed Reconstruction System in Size of Left DLT | unknown | N/A | 200 | Sichuan Cancer Hospital and Research InstituteOTHER | 0 | Feb 14, 2024 | clinicaltrials |
| NCT06259461 | Machine Learning to Construct an Association Model for Lung Cancer and Environmental Hormone | unknown | — | 128 | Pei-Hung LiaoOTHER | 1 | Feb 14, 2024 | clinicaltrials |
| NCT05829057 | The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1 | unknown | Phase 1 | 10 | Zhejiang UniversityOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT06245876 | Lung EpiCheck Biomarkers Development Study | unknown | — | 6,000 | Nucleix Ltd.INDUSTRY | 4 | Feb 12, 2024 | clinicaltrials |
| NCT03274479 | PBF-1129 in Patients With NSCLC | unknown | Phase 1 | 18 | Palobiofarma SLINDUSTRY | 1 | Feb 9, 2024 | clinicaltrials |
| NCT05163249 | Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC(FLOWERS) | unknown | Phase 2 | 44 | Guangdong Association of Clinical TrialsOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT05602259 | PROspective Trial on EOsinophilia in Non-Small Cell Lung Cancer (NSCLC).(PROTEON) | unknown | N/A | 200 | Centre Hospitalier Universitaire de LiegeOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT06234735 | Physical Activity Behavioral Change Intervention in Lung Cancer(RETOS) | unknown | N/A | 40 | University Ramon LlullOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT06250829 | Model to Predict pCR and IrAEs in Early Stage Non-small Cell Lung Cancer(Pre-PLaN) | unknown | — | 60 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT06251570 | Evaluation of Dual Task Performance and Respiratory Muscle Endurance in Patients With Lung Cancer | unknown | — | 60 | Hacettepe UniversityOTHER | 0 | Feb 9, 2024 | clinicaltrials |
| NCT01871454 | Safety of Pentoxifylline and Vitamin E With Stereotactic Ablative Radiotherapy (SABR) in Non-small Cell Lung Cancers | unknown | Phase 2 | 59 | University of LouisvilleOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05739695 | A Trial of Radial EBUS Versus VBN for the Peripheral Pulmonary Lesions | unknown | N/A | 300 | Ilya SivokozovOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT05946460 | Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity. | unknown | Phase 2 | 22 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT05526573 | Diagnostic Yeld of Ultrathin Bronchoscopy in Peripheral Pulmonary Lesions | unknown | — | 148 | Azienda Sanitaria-Universitaria Integrata di UdineOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06239623 | ERK Inhibitor JSI-1187 in Advanced Solid Tumors | unknown | Phase 1 | 60 | JS InnoPharm, LLCINDUSTRY | 1 | Feb 2, 2024 | clinicaltrials |
| NCT05573373 | Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer | unknown | Phase 1 | 40 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT05647590 | SBRT/RT in Oligometastatic Stage IV NSCLC | unknown | N/A | 10 | University Hospital OstravaOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT06232265 | An Observational Study on Predicting the Efficacy of Immunotherapy for NSCLC Based on LIRAscore | unknown | — | 108 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT06101394 | Development of a Fluorescent Visualization System for Non-visible Lung Cancer Nodules(RECOGNISE) | unknown | Phase 2 | 25 | University of Turin, ItalyOTHER | 1 | Jan 25, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Mar 28, 2024source: clinicaltrials